{'fraction_non_alphanumeric': 0.06398416886543536, 'fraction_numerical': 0.05474934036939314, 'mean_word_length': 4.703007518796992, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Stereotactic radiotherapy for multiple brain metastases].

BACKGROUND & OBJECTIVE
Stereotactic radiotherapy (SRT) has obvious advantages in treating intracranial tumors, but there are few reports about application of SRT to multiple intracranial tumors. This paper summarized the therapy outcome of patients with multiple brain metastases, and evaluated the efficacy and application of SRT.


METHODS
Clinical data of 136 patients with multiple brain metastases received radiotherapy from Jun. 1996 to Dec. 2002 were reviewed. Of the 136 patients, 52(38.2%) received conventional radiotherapy alone (CR group), 84(61.8%) received SRT or SRT plus whole brain radiotherapy (SRT group).


RESULTS
Clinical effective rate, and elimination rate of brain metastases (diameter of > 20 mm) were significantly higher in SRT group than in CR group (96.4% vs. 86.5%, P=0.02; 70.4% vs. 36.0%, P=0.007). Persistent brain edema rate was 8.3% in SRT group, and 9.6% in CR group (P=0.767). Intracranial tumor recurrence rate was 25.0% in SRT group, and 19.4% in CR group (P=0.653). Median survival time was significantly longer in SRT group than in CR group (10.5 months vs. 6.5 months, P=0.014); 1-year survival rate was significantly higher in SRT group than in CR group (40.5% vs. 21.2%, P=0.023).


CONCLUSION
Reasonable application of SRT could improve life quality and treatment outcome of patients with multiple brain metastases, reduce intracranial tumor recurrence and radiation damage, and prolong patients'survival time.